A Safety and Efficacy Study of Enzalutamide in Indian Patients with Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Docetaxel-Based Chemotherapy

Trial Identifier:	9785-CL-0413
Sponsor:	Astellas Pharma Inc.
Start Date:	September 2018
Primary Completion Date:	February 2024
Study Completion Date:	February 2024
Condition:	Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
India	Ahmedabad, India
India	Hubli, India
India	Kolkata, India
India	Nashik, India
India	New Delhi, India
India	Pune, India
India	Surat, India

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company